Last updated: September 8, 2026
Nepafenac is a topical ophthalmic nonsteroidal anti-inflammatory drug used primarily to control pain and inflammation after cataract surgery. The U.S. market includes branded products Nevanac and Ilevro, authorized generics, and other generic nepafenac ophthalmic suspensions. The drug has lost its core regulatory exclusivity and faces price pressure from generic competition, while premium once-daily positioning supports residual branded demand.
Product-level revenue is not disclosed by Novartis, Alcon, or generic manufacturers. Nepafenac’s financial trajectory must therefore be assessed through product lifecycle events, company portfolio disclosures, generic entry, prescription ophthalmology trends, and the competitive position of topical NSAIDs.
What is nepafenac used for and how does the FDA classify it?
Nepafenac is an ophthalmic prodrug converted in ocular tissues to amfenac, an active cyclooxygenase inhibitor. It reduces prostaglandin-mediated inflammation and pain following cataract extraction.
| Product |
Active ingredient |
Strength |
Dosing profile |
U.S. sponsor |
| Nevanac |
Nepafenac |
0.1% ophthalmic suspension |
Typically three times daily |
Novartis |
| Ilevro |
Nepafenac |
0.3% ophthalmic suspension |
Typically once daily |
Alcon |
| Generic nepafenac |
Nepafenac |
0.1% and 0.3% products |
Product-specific |
Multiple manufacturers |
The FDA approved Nevanac 0.1% in 2005 for the treatment of pain and inflammation associated with cataract surgery. The FDA approved Ilevro 0.3% in 2012 for the same broad postoperative setting, with once-daily dosing intended to improve convenience and adherence [1][2].
Nepafenac is a small-molecule ophthalmic drug. It is not a biologic and does not create biosimilar substitution risk. The principal competitive threat is generic substitution and competition from other topical ophthalmic NSAIDs.
What is the FDA and Orange Book status of nepafenac?
Nepafenac remains an FDA-approved ophthalmic product, but its original branded products no longer benefit from meaningful U.S. market exclusivity.
Nevanac is associated with FDA New Drug Application 21-234. Ilevro is associated with NDA 202-872. Current FDA labeling and approved generic products indicate that nepafenac is commercially available through both brand and generic channels [1][2][3].
FDA regulatory milestones
| Event |
Product |
Date |
| FDA approval |
Nevanac 0.1% |
2005 |
| FDA approval |
Ilevro 0.3% |
2012 |
| Generic approval pathway |
Nepafenac ophthalmic suspension |
After expiry or loss of key listed patent barriers |
| Current status |
Generic and branded ophthalmic products marketed |
Ongoing |
The Orange Book remains the authoritative source for listed patents, exclusivity codes, and approved NDA information. Orange Book listings can change through patent-listing updates, delistings, or changes in marketing status [3].
What patents protect nepafenac products?
The principal patent risk for nepafenac has shifted from compound protection to formulation, dosing, and delivery claims. The original compound and early ophthalmic formulation patents are no longer the primary commercial barrier in the U.S.
Nevanac patent position
Nevanac launched in 2005, placing its principal U.S. patent protection in a lifecycle stage that has now expired or become commercially weak. Any pediatric exclusivity associated with the product would have been temporary and would not materially alter the current generic-entry picture.
The commercially relevant patent categories historically included:
- Nepafenac ophthalmic compositions.
- Suspensions containing nepafenac and ophthalmically acceptable excipients.
- Conversion of nepafenac to amfenac in ocular tissues.
- Dosing methods for postoperative inflammation and pain.
- Particle-size and suspension-stability characteristics.
Ilevro patent position
Ilevro’s 0.3% concentration and once-daily dosing supported a later product lifecycle than Nevanac. Its patent estate likely provided a longer period of branded protection than the 0.1% product, but current generic availability demonstrates that the key U.S. barriers no longer prevent market entry.
The Ilevro lifecycle strategy relied on:
- Higher nepafenac concentration.
- Once-daily dosing.
- Post-cataract pain and inflammation indications.
- Product-specific suspension characteristics.
- Potential formulation and manufacturing claims.
Patent protection for Ilevro should be evaluated at the individual patent and claim level rather than by product name alone. A patent covering a formulation may not block an abbreviated new drug application if the generic product uses a non-infringing formulation or obtains approval through a different labeling strategy.
When did nepafenac lose exclusivity?
Nepafenac lost practical market exclusivity in stages rather than on a single date.
Nevanac’s commercial protection eroded first because it launched earlier and used a lower-concentration formulation. Ilevro retained a later branded lifecycle because it was approved in 2012 and differentiated through once-daily 0.3% dosing.
| Exclusivity component |
Nevanac |
Ilevro |
| New chemical entity exclusivity |
Expired |
Expired |
| Core patent protection |
Expired or no longer commercially blocking |
Later-expiring formulation and method claims, where applicable |
| Pediatric exclusivity |
Not currently relevant |
Not currently relevant |
| Generic availability |
Yes |
Yes or increasingly available, depending on market and product |
| Current market structure |
Brand plus generics |
Brand plus generics |
The practical entry date for each generic depends on the ANDA applicant, Paragraph IV certification, patent litigation, settlement terms, and FDA approval timing. A patent expiration date alone does not establish the actual launch date.
How many patents cover nepafenac?
There is no single stable number because patent scope differs by jurisdiction, product, assignee, prosecution history, continuation practice, and current Orange Book status.
The relevant patent groups are:
- Compound patents covering nepafenac or related chemical matter.
- Ophthalmic formulation patents covering suspensions, excipients, viscosity, particle size, or stability.
- Method-of-use patents covering postoperative inflammation or pain.
- Dosing patents covering once-daily or concentration-specific administration.
- Manufacturing patents covering crystallization, particle engineering, or suspension production.
The strongest remaining commercial claims are generally those that create a practical barrier to generic substitution, such as claims tied to a specific approved formulation or a narrowly defined dosage regimen. Broad historical patents have less commercial value after generic products have entered.
What generic entry risks exist for nepafenac?
Generic entry risk is high.
Nepafenac is a topical small molecule with an established ophthalmic use, known pharmacology, and multiple approved products. Generic manufacturers can pursue ANDA approval by demonstrating pharmaceutical equivalence and bioequivalence under FDA requirements applicable to ophthalmic suspensions [4].
Key generic-entry drivers
- The active ingredient is well characterized.
- The products are locally administered rather than systemically absorbed for therapeutic effect.
- Cataract surgery generates recurring demand.
- Generic manufacturers can target the 0.1% and 0.3% strengths.
- Physicians and pharmacies are familiar with topical NSAID substitution.
- Payers have an incentive to prefer lower-cost products.
Generic competition can reduce branded net prices even when branded products remain available. The erosion rate depends on the number of approved ANDAs, pharmacy benefit design, surgeon prescribing behavior, and the ability of the brand to retain institutional or specialty-pharmacy contracts.
Which companies are challenging nepafenac patents?
Publicly visible U.S. generic competition includes manufacturers that have obtained FDA approval for nepafenac ophthalmic suspension products. Companies active in ophthalmic generics have included Apotex, Sandoz, Teva, Dr. Reddy’s Laboratories, and other ANDA sponsors, depending on strength, market period, and product status [5].
A complete assessment of Paragraph IV activity requires matching each ANDA to:
- The relevant NDA.
- The Orange Book patent list at the time of certification.
- The ANDA sponsor.
- Any patent litigation docket.
- The final FDA approval date.
- The launch or settlement status.
Public patent litigation has not created a durable barrier comparable to the litigation surrounding high-value systemic drugs. The commercial risk is primarily cumulative generic price erosion rather than a single blocking lawsuit.
What patent litigation and settlement agreements affect nepafenac?
Nepafenac does not have a major current U.S. patent dispute profile comparable to leading branded drugs with billions of dollars in annual sales.
The main litigation scenarios were historically linked to Paragraph IV certifications against listed formulation or method patents. A generic applicant could challenge validity, enforceability, or infringement. The brand owner could then seek the Hatch-Waxman automatic stay, subject to statutory requirements and litigation timing [6].
No broadly reported settlement agreement has established a long-term, market-defining exclusivity position for nepafenac. If a settlement existed for a particular ANDA, its effect would generally be limited to that sponsor, the covered strength, the agreed launch date, and any authorized-generic terms.
What formulations are protected by nepafenac patents?
Nepafenac formulation protection has centered on ophthalmic suspensions rather than novel delivery platforms.
Relevant formulation features
- 0.1% nepafenac suspension.
- 0.3% nepafenac suspension.
- Particle-size distribution.
- Suspending agents.
- Wetting agents and surfactants.
- Preservatives.
- Viscosity modifiers.
- pH and osmolarity control.
- Physical stability during storage.
- Uniform dose delivery after shaking.
Ilevro’s higher concentration and once-daily administration provided the strongest lifecycle-management distinction from Nevanac. That distinction supported premium pricing during the protected period but became less durable after generic products reached the market.
Manufacturing know-how can remain commercially relevant after patent expiry. Consistent particle engineering, suspension uniformity, sterility assurance, filling, and packaging are important for ophthalmic products. These capabilities raise execution costs but generally do not prevent a capable generic manufacturer from entering.
How does nepafenac compare with bromfenac and ketorolac?
Nepafenac competes in the postoperative ophthalmic NSAID segment with bromfenac and ketorolac.
| Drug |
Typical U.S. positioning |
Dosing advantage |
Generic pressure |
Main commercial weakness |
| Nepafenac 0.1% |
Post-cataract inflammation and pain |
Established product |
High |
More frequent dosing |
| Nepafenac 0.3% |
Once-daily postoperative treatment |
Convenience |
High |
Premium pricing after generic entry |
| Bromfenac |
Postoperative inflammation and pain |
Often once or twice daily, depending on product |
High |
Multiple branded and generic alternatives |
| Ketorolac |
Postoperative inflammation and pain |
Established low-cost option |
Very high |
Older product and frequent dosing |
Nepafenac’s clinical and commercial differentiation is strongest against older multi-dose regimens. Against once-daily bromfenac, the differentiation narrows. Surgeons may choose based on formulary terms, familiarity, tolerability, preservative content, dosing, and payer coverage rather than a large clinical separation.
What is the financial trajectory for nepafenac?
Nepafenac’s financial trajectory follows the standard ophthalmic product lifecycle:
- Launch and adoption: Nevanac established the product in the postoperative cataract market.
- Premium expansion: Ilevro extended the franchise through higher concentration and once-daily dosing.
- Patent and exclusivity erosion: Generic entry reduced pricing power.
- Mature-market decline: Brand sales shifted toward retained prescribers, contract accounts, and patients with limited generic substitution.
- Generic-volume phase: Industry revenue continued through multiple manufacturers, but manufacturer-level margins compressed.
Novartis reported ophthalmology sales at a portfolio level and later transferred its Alcon ophthalmology business to Alcon in the 2019 transaction. Alcon subsequently reported pharmaceutical and surgical businesses at broader portfolio levels rather than consistently disclosing Ilevro revenue as a standalone line item [7][8].
As a result, there is no reliable public annual revenue series for nepafenac alone. The appropriate financial indicators are:
| Indicator |
Current implication |
| Brand unit demand |
Declining or pressured by substitution |
| Brand net price |
Lower than during protected commercialization |
| Generic unit volume |
Supported by cataract procedure demand |
| Generic price |
Declines as supplier count increases |
| Market growth |
Linked to cataract surgery volume, not exclusivity |
| Margin profile |
Higher for differentiated brand products, lower for commodity generics |
| Revenue concentration |
Distributed across brand owners and generic manufacturers |
Cataract surgery volume provides a structural demand base. Aging populations and increasing surgical treatment of cataracts support procedure growth, but that demand does not restore monopoly pricing once multiple generic suppliers are active.
What generic launch scenarios exist for nepafenac?
Scenario 1: Gradual multi-supplier erosion
Several generic manufacturers enter without a major shortage. Pharmacies shift toward lower-cost products, and branded nepafenac retains a smaller premium segment.
Scenario 2: Rapid brand displacement
Major payers and pharmacy chains adopt generic substitution quickly. The brand loses substantial volume within the first year of broad generic availability.
Scenario 3: Limited substitution for the 0.3% product
Surgeons continue prescribing branded or authorized-generic 0.3% nepafenac because of dosing familiarity, product availability, or contract terms. Price erosion is slower than for 0.1% nepafenac.
Scenario 4: Supply-driven price volatility
A small number of manufacturers control supply, creating temporary shortages or price increases. This can preserve short-term brand demand but does not change the underlying patent position.
What geographic coverage does nepafenac have?
Nepafenac is marketed in multiple jurisdictions, but patent and regulatory outcomes vary by country. U.S. generic entry does not determine European, Canadian, Japanese, or emerging-market exclusivity.
Relevant geographic variables include:
- National patent term and supplementary protection rights.
- Local approval standards for ophthalmic suspensions.
- Reference-product requirements.
- Reimbursement rules.
- Pharmacy substitution laws.
- Local manufacturing capacity.
- Tender purchasing by hospitals and surgical centers.
The commercial value of residual patent rights is generally higher in jurisdictions where generic substitution is slower or where local registration and manufacturing requirements limit immediate competition.
How strong is the nepafenac patent estate?
The current patent estate is commercially weak in the United States relative to the product’s earlier lifecycle.
Strengths
- Established clinical use.
- Multiple formulation distinctions.
- Potentially valuable know-how in ophthalmic suspension manufacturing.
- Recurring demand from cataract surgery.
Weaknesses
- Core exclusivity has expired.
- Generic products are available.
- Formulation claims can be designed around.
- Method-of-use claims may have limited practical blocking power.
- The active ingredient is a mature small molecule.
- No biologic manufacturing barrier exists.
Nepafenac is therefore a mature, defensible ophthalmic franchise only where brand equity, supply reliability, contracting, or dosing convenience creates value. It is not a high-strength patent asset in the current U.S. market.
Is there biosimilar risk for nepafenac?
No. Biosimilars are not relevant because nepafenac is a small-molecule drug.
The relevant regulatory pathway is the ANDA pathway for generic drugs, not the abbreviated biologics license application pathway under the Public Health Service Act. Competition will come from generics, authorized generics, private-label ophthalmic products, and competing NSAID products [4].
What licensing deals affect nepafenac?
The most important strategic transaction was Alcon’s separation from Novartis, which transferred the Alcon ophthalmology portfolio, including Ilevro-related commercial assets, into the independent Alcon business [7].
No major recent licensing transaction has made nepafenac a strategic growth asset comparable to a novel ophthalmology drug. The product is best viewed as a mature commercial franchise with residual cash flow rather than a platform for significant licensing value.
Key Takeaways
- Nepafenac is an established topical ophthalmic NSAID used mainly after cataract surgery.
- Nevanac 0.1% was FDA-approved in 2005; Ilevro 0.3% was approved in 2012.
- Core U.S. exclusivity has expired, and generic competition is established.
- Ilevro’s main lifecycle advantage was once-daily dosing and higher concentration.
- The relevant intellectual property covers formulations, dosing, methods of use, and manufacturing rather than a commercially powerful current compound patent.
- Paragraph IV and patent-litigation risk is materially lower than for major systemic products with large protected markets.
- Biosimilar risk does not apply.
- Product-level revenue is not publicly disclosed by Novartis, Alcon, or generic manufacturers.
- Future revenue depends on cataract surgery volume, generic supplier count, payer substitution, and brand retention.
- Nepafenac has mature-market cash-flow value but limited U.S. patent-driven upside.
FAQs About Nepafenac Patents, Pricing, and Market Competition
Does nepafenac still have patent protection in the United States?
Historical patents protected nepafenac products, but current U.S. market protection is weak because generic products are available. The Orange Book should be used for the current patent status of each NDA.
Is Ilevro stronger than Nevanac commercially?
Ilevro had stronger lifecycle positioning because its 0.3% concentration supported once-daily dosing. That advantage improved convenience but did not prevent eventual generic competition.
Can a generic manufacturer launch nepafenac without copying Ilevro?
Yes. An ANDA applicant can pursue a formulation that meets FDA requirements without copying every branded formulation feature, subject to patent certification and any enforceable claims.
Does cataract surgery growth offset nepafenac price erosion?
Cataract surgery growth supports unit demand, but it generally does not offset the pricing decline that follows multi-supplier generic entry.
Is nepafenac a good licensing target?
Nepafenac is more attractive as a mature ophthalmic cash-flow or supply-chain asset than as a patent-protected licensing opportunity. Its value depends on manufacturing efficiency, contracting, distribution, and market access.
References
- U.S. Food and Drug Administration. (2005). Nevanac (nepafenac ophthalmic suspension) prescribing information.
- U.S. Food and Drug Administration. (2012). Ilevro (nepafenac ophthalmic suspension) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
- Alcon Inc. (2019). Annual report and Form 10-K.
- Novartis AG. (2019). Annual report.
